October 6, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG-COORDINATED NCTN TRIALS

BY COMMITTEE

76% of Calendar Year is Past

Committee Annual
Base
Accrual²		 Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
BREAST 472 1014 214% 772 542 991
ERLYTX 54 62 114% 47 8 62
GI 100 97 97% 74 -3 100
GU 256 284 110% 216 28 280
LEUK 354 751 212% 572 397 737
LUNG 817 550 67% 419 -267 555
LYMPH 181 366 202% 279 185 349
MELAN 364 0 0% 0 -364 0
MMYEL 192 108 56% 82 -84 103
MULT 25 43 173% 33 18 51
Total 2815 3275   2494 460 3228

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 6, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG-COORDINATED NCORP TRIALS

BY COMMITTEE

76% of Calendar Year is Past

Committee Annual
Base
Accrual²		 Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
CCD 578 205 35% 156 -373 187
PEOLC 52 30 58% 23 -22 69
PREV 169 0 0% 0 -169 0
SXQOL 958 603 63% 459 -355 588
Total 1757 838   638 -919 844

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 6, 2026 Page

CURRENT AND PROJECTED ACCRUAL

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG CTP TRIALS

BY STUDY

76% of Calendar Year is Past

Committee Study Projected
2026
Accrual		 2026
Accrual
to date		 Accrual
Last
12 Months
ERLYTX 21CTP.HN01 13 10 10
LEUK 21CTP.LEUK01 9 7 7
Total   22 17 17

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 6, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG INSTITUTIONS

TO ANY NCTN TRIAL

BY COMMITTEE

76% of Calendar Year is Past

Committee Annual Base Accrual² Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
BREAST 352 688 195% 524 336 705
ERLYTX 42 46 108% 35 4 47
GI 157 127 81% 97 -30 124
GU 399 295 74% 225 -104 293
LEUK 182 340 187% 259 158 341
LUNG 551 352 64% 268 -199 354
LYMPH 173 289 166% 220 116 276
MELAN 228 8 3% 6 -220 8
MMYEL 135 70 51% 53 -65 65
MULT 14 18 134% 14 4 20
OTHER 57 63 110% 48 6 59
Total 2290 2296   1749 6 2292

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 6, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG INSTITUTIONS

TO ANY NCORP TRIAL

BY COMMITTEE

76% of Calendar Year is Past

Committee Annual Base Accrual² Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
CCD 534 161 30% 123 -373 155
GI 0 1 .% 1 1 1
PEOLC 37 28 74% 21 -9 56
PREV 341 223 65% 170 -118 229
SXQOL 665 496 74% 378 -169 481
Total 1577 909   693 -668 922

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 6, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED NCTN STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
BREAST III S2206: Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 10/30/2023 35 419 960 11.8 Jul-2030 6.7
    S2212: Breast, TNBC, Neoadj Chemo + Pembro 07/21/2023 38 1719 2400 71.7 Jul-2027 4.0
    S2511: Brst, de novo StgIV oligo, locoreg tx vs SOC 08/18/2026 1 0 534      
ERLYTX II SN2426: cSCC, IC Met/Inop, Amivantamab v Cetuximab 01/28/2026 8 11 86 1.7 Jul-2030 4.4
  II-III S2012: Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo 12/02/2021 58 169 189 3.7 Mar-2027 5.3
  III S2505: Sarcoma, Stg II-IIIB, Surg + Short vs Std RT 07/06/2026 3 0 296      
GI II S2104: Panc,Resect High-risk,Postop Adj Chemo vs Obs 10/14/2021 59 110 154 2.8 Jan-2028 6.2
  II-III S2303: Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo 05/06/2024 29 121 224 5.2 May-2028 4.0
  III S2433: PANC, KRAS WT, Met, SOC Chemo +/- Panitumumab 12/26/2025 9 1 94 0.2 > 15 Yrs > 15 Yrs
GU II S2210: Pros, High Risk, BRCA, Neoadj Carbo 08/14/2023 37 6 44 0.0    
    S2427: Blad, MIBC, RT + Pembrolizumab 09/04/2025 13 52 111 7.3 Jun-2027 1.8
  III S1802: Pros, Stg IV, SST ± Surg/RT to Primary Tum 09/17/2018 96 1058 1273 8.2 Dec-2028 10.2
    S1931: RENAL, Stg IV, IO + Nephrectomy. vs IO Only 11/16/2020 70 162 336 2.2 Jun-2033 12.6
    S2312: Pros, MCRPC, Cab +/- Carb 09/03/2024 25 72 500 4.5 Sep-2034 10.0
    S2419: Renal, adv clear cell, IO +/- Biotx, BIOFRONT 04/22/2026 5 35 718 6.4 Sep-2035 9.4
LEUK II MM1OA-S03: AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena 04/01/2025 18 29 102 3.5 Jun-2028 3.2
    MM1OA-S04: MyeloMATCH: AML, ASTX727 + Ven (28D v 14D) 07/22/2026 2 1 126      
    MM1YA-S01: AML, High Risk, Age <60, 7+3 vs experimental 05/16/2024 28 91 335 4.0 Nov-2031 7.5
    S2507: ALL/ALAL, KMT2A-trans, Blina +/- Revumenib 09/22/2026 0 0 90      
  III S1925: CLL/SLL, Newly Dx HR, Early vs Delayed V+O 12/14/2020 69 210 247 4.8 May-2027 6.4
    S2504: Richter Trans., Untreated, R-CHOP +/- Pirto 06/01/2026 4 1 102 0.2 > 15 Yrs > 15 Yrs
  OTHER MYELOMATCH: MSRP for the NCI myeloMATCH Clinical Trials 05/16/2024 28 1335   52.8 .- . .
LUNG II S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu 04/03/2023 42 28 44 0.5 Jun-2029 6.2
    S1900J: MET Amplification: Amivantamab Hyaluronidase 09/27/2024 24 4 88 0.0    
    S1900K: MET Exon 14: Tepotinib +/- Ramucirumab 12/18/2023 33 30 56 1.0 Dec-2028 5.0
    S1900N: AGAs: SG alone, I alone, or SG + I 08/03/2026 2 1 117      
    S2409: ESCLC, Durvalumab +/- Biomarker Directed Tx 09/08/2025 12 18 900 2.3 > 15 Yrs > 15 Yrs
  II-III S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab 04/28/2025 17 143 378 9.7 Oct-2028 3.4
  III S2414: NSCLC, Stg II-IIIB, Durva vs Surveillance 03/14/2025 18 14 306 1.0 > 15 Yrs > 15 Yrs
  OTHER LUNGMAP: NSCLC, Adv, Master 01/28/2019 92 4135   28.5 .- . .
LYMPH II S2114: NHL, Rel/Ref, CD19 CAR-T +/- Consolidation 02/23/2023 43 253 396 8.8 Feb-2028 5.0
    S2207: LBCL, Transplant Inelig, Targeted Tx + Tafa 06/30/2023 39 42 173 0.5 > 15 Yrs > 15 Yrs
    S2506: NHL, R/R MZL, Mozun +/- Zanu or Pola 08/18/2026 1 0 138      
  III S2308: FL, LTB, Mosunetuzumab vs Rituximab 08/01/2024 26 433 600 23.5 May-2027 2.8
MMYEL II S2005: WM, Prev. Untreated, I/R or Z v V/R 06/24/2021 63 45 92 3.8 Oct-2027 6.3
  III S1803: MM, Maintenance, Len vs Len/Dara 06/27/2019 87 1338 1100 0.0    
    S2209: MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 05/30/2023 40 148 510 3.8 Aug-2034 11.2
    S2213: AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 12/01/2023 34 52 142 1.8 Nov-2030 6.9
MULT II S2101: Melan or HNSCC, Adv, Cabo + Nivo 10/14/2022 47 109 220 3.7 Apr-2029 6.5
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

October 6, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED NCORP STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
CCD III S1703: Met Breast, STM-monitoring v Usual Care 07/16/2018 98 477 498 3.7 Mar-2027 8.6
    S2417CD: Colrec Surv, Follow-up w/ CTAC site 08/04/2025 14 133 654 13.2 Jan-2030 4.4
    S2424CD: A-PACT vs SOC for GOC communication 06/01/2026 4 5 1000 1.2 > 15 Yrs > 15 Yrs
PEOLC III S1501: Surv, Breast Stg IV, Card Tox w/ Carvedilol 09/15/2017 108 402 491 2.3 Dec-2029 12.2
    S2408: Panc Fistula Prevention, Lanreotide 02/14/2025   63 274      
SXQOL III S2205: ICE COMPRESS: Reduction of CIPN from Taxanes 03/16/2023 42 683 777 16.7 Mar-2027 4.0
  OTHER S2013: I-CHECKIT: ICI toxicity risk prediction study 08/16/2021 61 2660 3609 34.0 Jan-2029 7.4
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

October 6, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED CTP STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
ERLYTX II 21CTP.HN01: HN, Recur/Met, Amivantamab + Chemo 03/05/2026 7 10 50 1.3 Apr-2029 3.1
LEUK II 21CTP.LEUK01: ALL, Ph+, Asciminib, Dasatinib and Prednisone 12/11/2025 9 7 55 1.2 Mar-2030 4.2
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.